BOSTON, Sept. 15, 2021 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is proud to announce it has entered into a Sponsored Research Agreement with Tufts ...

Remedium's lead candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a ...

This strategic collaboration will leverage Lilly's deep expertise in metabolic diseases and Remedium's proprietary subcutaneously administered gene delivery system to develop and commercialize ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The biotechnology company is developing a first-in-class adjustable-dose gene therapy platform called PrometheusTM, which can replace a broad range of multi-protein injection treatments with a single ...

AAV2-FGF18 appears to have a wide therapeutic safety window and is able to induce chondrogenesis at very low, locally administered doses The FGF18 gene therapy appears to induce chondrogenesis by ...